Quanterix to Present at Cowen’s 43rd Annual Health Care Conference

On February 28, 2023 Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, reported that Chief Executive Officer Masoud Toloue will present at Cowen’s 43rd Annual Health Care Conference (Press release, Quanterix, FEB 28, 2023, View Source [SID1234627914]). Quanterix’s session will take place on Tuesday, March 7, 2023, at 9:50 a.m. EST and will be made available to attendees and, via webcast, the general public. In addition to the session, Quanterix will also host one-on-one meetings with institutional investors during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen’s 43rd Annual Health Care Conference will take place March 6 – 8, 2023, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.

Webcast Information
To access the live audio webcast of Quanterix’s presentation at the conference, please visit: https://wsw.com/webcast/cowen132/qtrx/2062158. Quanterix’s session will take place on Tuesday, March 7, 2023, at 9:50 a.m. EST.

Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of Quanterix’s website.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa technology, visit: View Source

Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results

On February 28, 2023 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent", or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, reported financial results for its fourth quarter and full year ended December 31, 2022 (Press release, Fulgent Genetics, FEB 28, 2023, View Source [SID1234627913]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth Quarter 2022 Results:

Total Revenue of $67.7 million
Core Revenue1 grew 97% year-over-year to $55.0 million
GAAP loss of $23.8 million, or $0.80 per share
Non-GAAP loss of $14.2 million, or $0.48 per share
Adjusted EBITDA loss of $15.1 million
Cash from operations of $33.2 million
Cash, cash equivalents, and investments in marketable securities, including investments pending settlement, of $872.0 million as of December 31, 2022
Repurchased approximately 815,000 shares of common stock at an aggregate cost of $29.1 million under the stock repurchase program announced in March 2022
Full Year 2022 Results:

Total Revenue of $619.0 million
Core Revenue1 grew 95% year-over-year to $181.5 million
GAAP income of $143.4 million, or $4.63 per share
Non-GAAP income of $179.4 million, or $5.79 per share
Adjusted EBITDA of $257.1 million
Cash from operations of $253.5 million
Repurchased over 1.8 million shares of common stock at an aggregate cost of $74.3 million under the stock repurchase program announced in March 2022
Note:

1) Core Revenue excludes revenue from COVID-19 testing products and services including COVID-19 NGS testing revenue.

Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under "Note Regarding Non-GAAP Financial Measures" and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.

Ming Hsieh, Chairman of the Board and Chief Executive Officer, said, "2022 was a transitional and transformative year for Fulgent, as we integrated the acquisitions of Inform Diagnostics and CSI Laboratories and acquired the Pharma business. As the COVID-19 pandemic continues to have a lesser impact, we are excited about the growth and momentum in our core business, with strength across our 3 business areas – precision diagnostics, anatomic pathology, and pharma services – and momentum in oncology and reproductive health, particularly with the expansion of oncologic carrier screening through Beacon787, also announced today. We have reorganized our Board of Directors and are on the path to transforming Fulgent from a genomic diagnostic service business into a fully integrated precision medicine company, focusing on oncology. In the meantime, we have a long runway of opportunity in the core business and see diagnostics as a dependable source of revenue and growth for Fulgent in the years ahead."

Paul Kim, Chief Financial Officer, said, "We are pleased with our results in 2022 and the trajectory of our core business. While the revenue profile of the Company without COVID testing revenue has implications for our bottom line, I believe we are poised for sustainable growth in the core business and to continue to generate cash. We are well positioned to execute our strategy while maintaining flexibility to capitalize on additional acquisition and strategic investment opportunities in the future."

Outlook:

For the first quarter of 2023, Fulgent expects:

Total Revenue of approximately $56.0 million
For the full year 2023, Fulgent expects:

Total Revenue of approximately $240.0 million
GAAP loss of approximately $2.50 per share
Non-GAAP loss of approximately $1.25 per share
Conference Call Information

Fulgent will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its fourth quarter and full year 2022 results. The call may be accessed through a live audio webcast in the Investor Relations section of the Company’s website, View Source An audio replay will be available at the same location.

Note Regarding Non-GAAP Financial Measures

Certain information set forth in this press release, including non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are non-GAAP financial measures. Fulgent believes this information is useful to investors because it provides a basis for measuring the performance of the Company’s business, excluding certain income or expense items that management believes are not directly attributable to the Company’s operating results. Fulgent defines non-GAAP income (loss) as net income (loss) calculated in accordance with accounting principles generally accepted in the United States of America, or GAAP, plus amortization of intangible assets, plus restructuring costs, plus acquisition-related costs, including banking fees and legal fees associated with the recent acquisitions, plus equity-based compensation expense, plus or minus the non-GAAP tax effect, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. The non-GAAP tax effect is calculated by applying the statutory corporate tax rate on the amortization of intangible assets, restructuring costs, acquisition-related costs, and equity-based compensation expense. Fulgent defines adjusted EBITDA income (loss) as GAAP income (loss) plus or minus interest (expense) income, plus or minus provisions (benefits) for income taxes, plus restructuring costs, plus acquisition-related costs, plus equity-based compensation expense, plus depreciation and amortization, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. Fulgent may continue to incur expenses similar to the items added to or subtracted from GAAP income (loss) to calculate non-GAAP income (loss) and adjusted EBITDA income (loss); accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of net income (loss) in evaluating the Company’s operating performance. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies.

Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development

On February 28, 2023 Tempus, a leader in artificial intelligence (AI) and precision medicine, reported a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development (Press release, Tempus, FEB 28, 2023, View Source [SID1234627912]). The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and development in oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. Pfizer also has access to Tempus’ broad range of capabilities that support therapeutic R&D, to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.

"Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics," said Eric Lefkofsky, Founder and CEO of Tempus. "This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine."

Nordic Nanovector ASA Results for the Second Half and Full Year 2022

On February 28, 2023 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") reported its results for the second half and full year 2022 (Press release, Nordic Nanovector, FEB 28, 2023, View Source [SID1234627911]). A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes will be held in-person today in Oslo and webcast live beginning at 8:30am CET – details below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jon Magne Asmyr, Chair of the Board, commented: The Company’s future is still unclear, and since the turn of the year the new Board has prioritised four important tasks: to get a new CEO/CFO in place; to reduce burn rate; to map the potential of the CD37-targeted immunotherapy platform and the early-stage solid tumour project; and to find strategic solutions that safeguard the interests of shareholders. We are happy to have solved the CEO and CFO situation with the interim appointment of Ludvik Sandnes and to see that the cost base has been significantly reduced. We continue to further evaluate Nordic Nanovector’s pipeline, and, at the same time, we are pursuing all potential strategic options. We hope that this this process will materialise into a proposed transaction that would be acceptable to shareholders."

Ludvik Sandnes, Interim CEO & CFO, commented: "2022 was an extremely difficult year for Nordic Nanovector. The former board and management made strong efforts to safeguard shareholder and company values culminating in the agreed merger proposal with APIM Therapeutics that was not supported by the required majority of shareholders. The clear goal in 2023 is to ensure Nordic Nanovector’s continued operation and to position it for a possible transaction that would benefit the current organisation, employees and shareholders. We continue to work hard, with our financial advisors Carnegie, to assess strategic options that may be open to the Company and will put forward any recommended proposals for resolution by the Company’s shareholders in due course."

H2’2022 Events

The former Board of Directors decided to discontinue the PARADIGME global Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line follicular lymphoma (3L R/R FL) patients, refractory to RTX/anti-CD20 based treatments
Betalutin profile did not fully meet objectives set out for the PARADIGME study with only one out of every three patients (ORR 31.1%) responding to treatment and median duration of response of 6.4 months]
Only one in seven patients had a complete response at three months (CRR 14.8%) with a median DoCR of 8.5 months
Both of the above results failed to meet the threshold for study success, which were minimum ORR of 40% and minimum CRR of 25%
Profile determined to be no longer sufficiently competitive to bring Betalutin to the market in the 3L R/R FL indication within a timeframe that made financial and commercial sense for the Company
The former Board implemented a restructuring of the Company to reduce costs
Staff numbers reduced to six as of 28 February 2023 from 40 as of 30 June 2022
Formal close down of PARADIGME initiated and expected to be concluded by the end of Q1’2023. The study results will be published in the required public access databases thereafter
All larger contracts have been terminated.
Further commitments related to the closure of PARADIGME during 2023 and transaction costs related to the proposed APIM merger bring the current uncommitted net cash level to approximately NOK 60m at the beginning of 2023.
Carnegie Investment Bank appointed to explore strategic options for the Company to optimise shareholder value
Proposal to combine with APIM Therapeutics agreed by the former Board of Directors and the APIM Board (announced 9 November 2022)
Proposal rejected by Shareholders at Extraordinary General Meeting (EGM) on 1 December 2022
Post-period events

Board and Management changes
The former Board of Directors resigned at the EGM (3 January 2023) and a new Board consisting of Jon Magne Asmyr (Chairperson), Eddie Berglund and Tina Bjørnlund Bønsdorff was elected, as well as a new Nomination Committee consisting of Hans Peter Bøhn (Chairperson), Jan-Tore Pedersen and Vegard Aavik
Eddie Berglund resigned from the Board on 19 January 2023
Ludvik Sandnes, former Chairperson of Nordic Nanovector (2013-2019), was appointed interim CEO & CFO as from 1 February 2023 replacing Malene Brondberg who transitioned out of the Company
Financial Highlights

(Figures in brackets = same period 2021 unless otherwise stated)

Revenues for the second half 2022 amounted to NOK 0.0 million (NOK 0.0 million). Revenues for the full year 2022 were NOK 0.0 million (NOK 0.0 million).
Total operating expenses for the second half 2022 were NOK 114.2 million (NOK 237.4 million). Total operating expenses for the full year 2022 amounted to NOK 317.4 million (NOK 442.4 million).
Comprehensive loss for the second half 2022 amounted to NOK 111 million (loss of NOK 237.6 million). Comprehensive loss for the full year 2022 was NOK 307.1 million (NOK 441.7 million).
Cash and cash equivalents amounted to NOK 98.7 million 31 December 2022 compared to NOK 287.4 million on 30 June 2022, and NOK 277.7 million on 31 December 2021.
Outlook

Following the decisions made in 2022 to discontinue the PARADIGME study and implement a restructuring of the Company, Nordic Nanovector believes that the best interests of shareholders will be served by thoroughly exploring all strategic options that may be available with the help of Carnegie as expert financial advisor.

As a publicly quoted company with a listing in Norway, remaining cash resources and a pipeline of CD37-targeted assets, the Company believes that there is an opportunity to crystalise value for shareholders through a potential strategic transaction.

No assurances can be given as to the outcome or timing of the ongoing review process. The Company will put forward any recommended proposals for resolution by shareholders in due course.

Several measures have been implemented to reduce the burn rate, and the Company’s current net cash is expected to finance its ongoing operations into Q2 of 2024.

Presentation and Webcast

A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes will be held in-person and webcast live today beginning at 8:30am CEST.

Venue: ADVOKATFIRMAET CLP DA, Sommerrogata 13, 0255 Oslo
The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2022 from 7:00am CEST the same day.

IR enquiries

Ludvik Sandnes, Interim CEO & CFO
[email protected]

RaySearch Laboratories: Year-end report 2022

On February 28, 2023 RaySearch Laboratories reported that in the fourth quarter of 2022, order intake increased by 49 percent and net sales rose 40 percent. Operating profit amounted to SEK 21 M (-17) (Press release, RaySearch Medical, FEB 28, 2023, View Source [SID1234627910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FOURTH QUARTER (OCTOBER – DECEMBER 2022)

Order intake SEK 514.4 M (345.0)
Net sales SEK 264.4 M (188.6)
Operating profit SEK 20.7 M (-16.6))
Profit after tax SEK 14.1 M (-16.0)
Profit per share before/after dilution SEK 0.41 (-0.47)
Cash flow SEK 42.8 M (-20.1)
Order backlog SEK 1,940.1 M (1,362,9) at the end of the period
TWELVE MONTHS (JANUARY – DECEMBER 2022)

Order intake SEK 1,218.5 M (807.8)
Net sales SEK 843.6 M (641.7)
Operating profit SEK 42.7 M (-53.3)
Profit after tax SEK 23.8 M (-47.3)
Profit per share before/after dilution SEK 0.69 (-1.38)
Cash flow SEK 46.8 M (-71.7)
SIGNIFICANT EVENTS DURING THE FOURTH QUARTER

RaySearch received its largest order ever when Ion Beam Applications S.A. (IBA) placed an order of 17.3 MEUR for RayStation and RayCare for installation at nine proton centers in Spain.
University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, in the United States, placed an order for RayStation.
CGN Medical Technologies placed an order for RayStation, which CGN sold together with IBA’s proton treatment system to Yangzhou Hospital in China.
Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in the United States, placed an order for RayStation.